Bio-IT World Contributed Commentary | Transparency is critical for all industries these days, but especially for the life sciences sector. When it comes to innovative services and products from emerging life sciences companies, transparency can be pivotal to preventing fraud and wasted investments.

Bio-IT World | As a Senior Data Scientist at the Parker Institute for Cancer Immunotherapy, Daniel Wells sees how discoveries in immunotherapy are rapidly changing how researchers develop treatment strategies for patients by integrating multiple molecular and clinical data types.

Bio-IT World | John-William Sidhom says the ideal scenario would be to have a system where scientific research asks the relevant questions, tech provides answers to those questions, and the physician implements those solutions for the most clinical impact.

Bio-IT World | St. Jude Children's Research Hospital has announced the real-time availability of clinical genome sequencing data on the St. Jude Cloud.

Bio-IT World | For decades, clinicians and researchers have been fascinated by fusion genes—genomic abnormalities that form when part of the DNA from one chromosome moves to another chromosome. This helps explain the growing popularity of the Genomenon's Mastermind suite of software tools, which is more inclusive of all documented fusions.

Bio-IT World | There is often a lack of understanding in drug discovery about how polyspecificity drives antibody toxicity. This shows polyspecificity is an underappreciated phenomenon in therapeutic antibody development, but that these unwanted properties can be fully improved by paratope refinement.

Bio-IT World | A 17-partner consortium in Europe is seeking to confirm the utility of a machine learning platform for better predicting promising compounds for drug development. The three-year initiative, which launched in June, represents the first large-scale deployment of blockchain technology to extract insights from multiple preclinical datasets without having to first pool the data.